Boardroom Alpha
Boardroom Alpha
RYAN · Current Report (Form 8-K) · Filed August 7, 2026

Ryan Specialty Holdings Inc — Current Report (Form 8-K)

Form
8-K
Filed
August 7, 2026
Period
Aug 4, 2026
Ticker
RYAN
Accession
0001849253-26-000040
Boardroom Alpha · Filing insights

Amendment extends back-to-back settlement with the Ryan Stock Option Trust for Second Tranche Executive Chairman options, preserving net neutrality.

About Ryan Specialty Holdings Inc
Market cap
$11.2B
1Y TSR
−25.4%
3Y TSR
−0.7%
Board grade
C-
Sector
Financial Services
CEO
Timothy William Turner
Last annual meeting: Apr 28, 2026 · View full Ryan Specialty Holdings Inc profile →
ryan-20260804
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2026
____________________
RYAN SPECIALTY HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
____________________
Delaware
001-40645
86-2526344
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
155 North Wacker Drive, Suite 4000
Chicago, Illinois
60606
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 312 784-6001
(Former Name or Former Address, if Changed Since Last Report)
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $0.001 par value
RYAN
The New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. o
Item 1.01 Entry into a Material Definitive Agreement.
On August 4, 2026, Ryan Specialty Holdings, Inc. (the “Company”) and the Ryan Stock Option Trust (the “Trust”), a trust
of which Patrick G. Ryan, the Company’s Executive Chairman, and Shirley W. Ryan, serve as trustees, entered into 
Amendment No.1 to Executive Chairman Option Settlement Agreement (the “Amendment”). The Amendment was entered
into in connection with the Company’s simultaneous grant of compensatory stock options (the “Second Tranche Executive
Chairman Stock Options”) for the purchase of 287,646 shares of the Company’s Class A common stock, par value $0.001
per share to certain employees of the Company under the Company’s 2021 Omnibus Incentive Plan. The Amendment
extends the back-to-back purchase arrangement between the Company and the Trust established under the Executive
Chairman Option Settlement Agreement, dated as of May 5, 2026, by and between the Company and the Trust (the
“Original Agreement”), to the Second Tranche Executive Chairman Stock Options, and all provisions of the Original
Agreement apply to the Amendment to the extent not inconsistent with the express terms of the Amendment. The purpose
of the Amendment is to make the grant and exercise of the Second Tranche Executive Chairman Stock Options net neutral
to the Company’s outstanding share count while supporting the alignment of certain employees.
The description of the Amendment contained in this Current Report on Form 8-K is qualified in its entirety by reference to
the complete text of the Amendment, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
The following exhibits are furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
RYAN SPECIALTY HOLDINGS, INC. (Registrant)
Date:
August 7, 2026
By:
/s/ Mark S. Katz
Mark S. Katz
Executive Vice President, General Counsel and Corporate
Secretary
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Ryan Specialty Holdings Inc (RYAN)

Reference

Frequently asked questions

When did Ryan Specialty Holdings Inc file this 8-K?
Ryan Specialty Holdings Inc (RYAN) filed this Current Report (Form 8-K) with the SEC on August 7, 2026. The accession number assigned by EDGAR is 0001849253-26-000040.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Amendment extends back-to-back settlement with the Ryan Stock Option Trust for Second Tranche Executive Chairman options, preserving net neutrality. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Ryan Specialty Holdings Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Ryan Specialty Holdings Inc has filed under CIK 1849253, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer